ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Jonathan A. Ledermann(London Cancer), Anna Fagotti(Università Cattolica del Sacro Cuore), Christina Fotopoulou(Ovarian Cancer Action), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), W. Glenn McCluggage(Belfast Health and Social Care Trust), Charlie Gourley(Edinburgh Cancer Research), Frederik Marmé(Heidelberg University), Florence Joly(Centre François Baclesse), D. Fischerová(Charles University), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Alexandra Léary(Institut Gustave Roussy), Nicole Concin(Medical University of Vienna), Giovanni Scambia(Agostino Gemelli University Polyclinic), Sabrina Croce(Institut Bergonié), Christian Marth(Nordic Society of Gynecologic Oncology), Ane Gerda Zahl Eriksson(Memorial Sloan Kettering Cancer Center), Philippe Morice(Inserm), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Ronnie Shapira‐Frommer(Sheba Medical Center), Ignace Vergote(KU Leuven), David S.P. Tan(National University of Singapore), Ignacio Romero(Valencian Infertility Institute), Luis Chiva(Clinica Universidad de Navarra), Domenica Lorusso(Agostino Gemelli University Polyclinic), Pedro T. Ramírez(Houston Methodist), José Alejandro Pérez Fidalgo(INCLIVA Health Research Institute), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Xavier Matías‐Guiu(Universitat de Lleida), Conxi Lázaro(Institut d'Investigació Biomédica de Bellvitge), Shibani Nicum(London Cancer), David Cibula(Charles University), Isabelle Ray‐Coquard(Centre Léon Bérard), Claire Falandry(Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement), Ben Davidson(Oslo University Hospital), Philipp Harter(Kliniken Essen-Mitte), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Cristiana Sessa(Institute of Oncology Research), François Planchamp, Iain A. McNeish(Imperial College London), Çağatay Taşkıran(Koç University), Sven� Mahner(LMU Klinikum), Nicoletta Colombo(University of Milano-Bicocca), Willemien J. van Driel(The Netherlands Cancer Institute), C.A.R. Lok(The Netherlands Cancer Institute), Jalid Sehouli(Charité - Universitätsmedizin Berlin)
Cited by 277
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
|International Journal of Gynecological Cancer|2020|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k